Please assess the completion status of the following clinical trial:

Trial Title: BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage IIIB/IV or Relapsed NSCLC~* Age \>= 18 years~* At least one measurable lesion by RECIST (version 1.1)~* ECOG PS 0, 1, 2~* Hematologic profile~  * Hgb \> 8 g/dL, ANC \>= 2,000/m3, Platelet \>= 100,000/m3~* Hepatic profile~  * Total bilirubin \<= 1.5 x upper normal value~ * Transaminases \<= 3 x upper normal value \<= 5 x upper normal value in case of liver metastasis~* Creatinine \<= 1.5mg/dL~* Patients should be recovered from toxicities of previous treatment.~* Written informed consent by patient or surrogates~Exclusion Criteria:~* Patients who had been previously treated with chemotherapy for NSCLC~* Active infection requiring antibiotics treatment~* Prior diagnosis of other malignancy except radically treated basal cell or squamous cell carcinoma of the skin and carcinoma in situ of the uterine cervix~* Peripheral neuropathy \>= grade 2 by NCI CTCAE 4.0~* Uncontrolled hypertension, Acute myocardial infarction within 6 months Unstable angina, Congestive heart failure \>= NYHA grade 2 Uncontrolled significant arrhythmia~* Patients who entered other clinical trials within 4 weeks~* Pregnant or lactating women. women with child bearing age who are not willing to a contraceptive measure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Belotaxel plus Belloxa (Type: EXPERIMENTAL): Belotaxel 60 mg/m2 3 weekly (day 1) Belloxa 70 mg/m2 3 weekly (day 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).